[Use and value of the therapeutic neuroleptic-bromocriptine combination in schizophrenia]

¹Unité de traitement des Psychoses, S.H.U. de Psychiatrie Secteur IV, Limoges.

|October 1, 1995

Abstract:

Use and interest of therapeutic association bromocriptine-neuroleptic in schizophrenia. Twelve schizophrenic patients were treated by bromocriptine (7.5 mg.day) and neuroleptic. After one month, patients on this treatment showed a mean improvement of 29% on the total score of the positive and negative symptom scale. This results suggest that therapeutic association bromocriptine-neuroleptic may be used for schizophrenic patients.

Related Experiment Videos

[Use and value of the therapeutic neuroleptic-bromocriptine combination in schizophrenia]

Related Concept Videos

[Arguments for early treatment of refractory schizophrenia].

[Anxiolytics and mnemonic ability of the aged subject. Apropos of a double-blind study between tiapride and lorazepam].

[Double-blind comparative study of lorazepam and tiapride effects on the memory capacities of subjects over 60 years of age].

[The effects of the pandemic on students in a psychodynamic setting].

[The effects of the COVID-19 pandemic on BAPU students: What analyzes were made by clinicians? The specifics of student care needs in a crisis context].

Examining the relationship between the thinking styles and the motivation aspects of the individuals working in the health sector in Turkey during the COVID-19 pandemic: The case of hospital staff.

[Psychological impact of the COVID-19 pandemic on children and adolescents and treatments].

[Assessing psychological, anxiety, depression and stress levels of Senegalese general population during COVID-19 pandemic].

[Autism Spectrum Disorders: What the COVID-19 Pandemic Has Taught Us].

Simpson Grading and Risk of Recurrence in 4074 Meningioma Patients With Gross Total Resection.

In Vivo Direct Reprogramming: Current Progress and Future Prospects from Mechanisms to Therapeutic Application.

A meta-analysis of transjugular intrahepatic portosystemic shunt with or without embolization for esophageal and gastric variceal bleeding in decompensated liver cirrhosis.

Metrnl in mitigating radiation enteritis via label-retaining cells protection by modulating the c-KIT-WNT pathway.

Erratum: Author correction to "A neutrophil-biomimic platform for eradicating metastatic breast cancer stem-like cells by redox microenvironment modulation and hypoxia-triggered differentiation therapy" [Acta Pharm Sin B 13 (2023) 298-314].

Canine dental pulp stem cell-derived exosomes: Proteomic characterization and first xenogeneic application for post-castration wound healing in cats.

Related Experiment Videos

[Use and value of the therapeutic neuroleptic-bromocriptine combination in schizophrenia]

Abstract:

Related Concept Videos

Related Articles